Stocks and Investing
by (remove) : David Lebowitz
RSSJSONXMLCSV
Stocks and Investing
by (remove) : David Lebowitz
RSSJSONXMLCSV
Tue, September 17, 2024
Wed, September 4, 2024
Fri, May 3, 2024
Fri, February 23, 2024
Fri, February 16, 2024
Thu, February 8, 2024
Tue, November 7, 2023
Fri, June 30, 2023
Thu, April 27, 2023
Wed, April 5, 2023
Tue, February 21, 2023
Thu, November 3, 2022
Fri, July 15, 2022
Fri, June 10, 2022
Tue, June 7, 2022
Thu, May 12, 2022
Tue, May 10, 2022
Fri, April 29, 2022
Wed, April 13, 2022
Tue, March 15, 2022
Mon, March 7, 2022
Wed, March 2, 2022
Tue, March 1, 2022
Wed, February 23, 2022
Tue, January 18, 2022
Fri, November 19, 2021
Fri, October 29, 2021
Tue, October 12, 2021

David Lebowitz Maintained (ASND) at Strong Buy with Increased Target to $207 on, Sep 17th, 2024


Published on 2024-10-28 14:18:43 - WOPRAI, David Lebowitz
  Print publication without navigation


David Lebowitz of Citigroup, Maintained "Ascendis Pharma A/S" (ASND) at Strong Buy with Increased Target from $178 to $207 on, Sep 17th, 2024.

David has made no other calls on ASND in the last 4 months.



There are 6 other peers that have a rating on ASND. Out of the 6 peers that are also analyzing ASND, 0 agree with David's Rating of Hold.



These are the ratings of the 6 analyists that currently disagree with David


  • Li Watsek of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $170 on, Monday, September 16th, 2024
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $175 on, Wednesday, September 4th, 2024
  • Yaron Werber of "TD Cowen" Maintained at Strong Buy with Decreased Target to $157 on, Wednesday, September 4th, 2024
  • Jessica Fye of "JP Morgan" Maintained at Buy with Decreased Target to $165 on, Wednesday, September 4th, 2024
  • Kelly Shi of "Jefferies" Maintained at Strong Buy with Increased Target to $196 on, Tuesday, August 13th, 2024
  • Alex Thompson of "Stifel" Initiated at Strong Buy and Held Target at $200 on, Friday, May 31st, 2024
Contributing Sources